HemiClor (hydrochlorothiazide 6.25 mg)
Hypertension in adults
ApprovedActive
Key Facts
About PRM Pharma
PRM Pharma is a specialty pharmaceutical company with a focused mission to develop and commercialize lower-dose versions of established drugs. The company leverages the FDA's 505(b)(2) pathway for efficient development, capitalizing on existing safety and efficacy data to bring optimized dosing to patients, particularly in hypertension and other therapeutic areas. Its first commercial product, HemiClor® (a low-dose hydrochlorothiazide), is now available in U.S. pharmacies, marking its transition to a commercial-stage entity. The leadership team, led by founder and CEO Joseph T. McDevitt, has a proven track record in low-dose drug development, having previously created the widely prescribed Microzide®.
View full company profile